NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML

RecruitingN/A

Sponsor: Carmen Fava

Conditions: Leukemia,Myeloid, Chronic

Interventions: non interventional study with the use of biological samples.

Countries: Italy

Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity. In the case of Chronic Myeloid Leukemia (CML), treatment with Tyrosine Kinase Inhibitors (TKIs) restores immunosurveillance; in particular deep molecular response (DMR) is associated with increased levels of NK and CD8+ Tcells. There is no literature on the effects of GM on CML outcomes. This project aims to identify a microbial signature associated with a higher probability of achieving DMR.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age \> 18 years old
* Chronic Myeloid Leukemia Patients
* Any stage of the disease

Exclusioni Criteria:

none

Locations (1)

Torino, Italy